

Title (en)
C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Title (de)
CSA REZEPTOR ANTAGONISTEN, DIE WESENTLICH KEINE AGONIST AKTIVITÄT BESESSEN

Title (fr)
ANTAGONISTES DU RECEPTOR C5a NE PRESENTANT PRATIQUEMENT AUCUNE ACTIVITE AGONISTE

Publication
EP 0733107 A1 19960925 (EN)

Application
EP 94931155 A 19941116

Priority
• IB 9400359 W 19941116
• US 16259193 A 19931206

Abstract (en)
[origin: WO9516033A1] Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no anaphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.

IPC 1-7
C12N 15/12; C12N 15/62; C07K 14/47; C07K 16/18; G01N 33/68; A61K 38/17; A61K 39/395

IPC 8 full level
A61K 38/00 (2006.01); **A61K 39/395** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 17/00** (2006.01); **A61P 19/06** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07H 21/04** (2006.01); **C07K 14/47** (2006.01); **C07K 16/18** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/12** (2006.01); **C12P 21/02** (2006.01); **C12P 21/08** (2006.01); **G01N 33/566** (2006.01); **C12R 1/19** (2006.01)

CPC (source: EP)
A61P 1/00 (2017.12); **A61P 1/16** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 13/02** (2017.12); **A61P 15/00** (2017.12); **A61P 17/00** (2017.12); **A61P 19/06** (2017.12); **A61P 25/00** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07K 14/472** (2013.01); **C07K 16/18** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/00** (2013.01)

Citation (search report)
See references of WO 9516033A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9516033 A1 19950615; AU 698919 B2 19981112; AU 8002594 A 19950627; BR 9408265 A 19961210; CA 2176825 A1 19950615; CN 1142854 A 19970212; EP 0733107 A1 19960925; FI 962319 A0 19960603; FI 962319 A 19960603; HU 9601538 D0 19960729; HU T75990 A 19970528; IL 111792 A0 19950124; JP H09506258 A 19970624; MX PA99008669 A 20040901; NO 962348 D0 19960605; NO 962348 L 19960805; NZ 274917 A 19980325; TW 429262 B 20010411; ZA 949647 B 19950606

DOCDB simple family (application)
IB 9400359 W 19941116; AU 8002594 A 19941116; BR 9408265 A 19941116; CA 2176825 A 19941116; CN 94194914 A 19941116; EP 94931155 A 19941116; FI 962319 A 19960603; HU 9601538 A 19941116; IL 11179294 A 19941128; JP 51606895 A 19941116; MX 9908669 A 19990921; NO 962348 A 19960605; NZ 27491794 A 19941116; TW 83111578 A 19941213; ZA 949647 A 19941205